Immunome (IMNM) Preferred Stock Liabilities (2019 - 2020)
Immunome (IMNM) reported Preferred Stock Liabilities of $48.4 million for Q3 2020, up 75.8% on a YoY basis from $27.5 million in Q4 2019, and little changed quarter-over-quarter from $48.4 million in Q2 2020.
Immunome (IMNM) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Immunome has reported Preferred Stock Liabilities for 2 years, with the latest figure at $48.4 million in Q3 2020.
- For the quarter ending Q3 2020, Preferred Stock Liabilities rose 75.8% year-over-year to $48.4 million; the trailing twelve-month figure through Sep 2020 stood at $48.4 million (up 75.8% YoY), and the FY2019 full-year result was $38.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2020 stood at $48.4 million, roughly flat from $48.4 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $48.4 million in Q2 2020, with the low at $27.5 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Immunome | 2.12 Bn | 1.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 48.37 Mn |
| Jun 30, 2020 | 48.39 Mn |
| Dec 31, 2019 | 38.89 Mn |
| Sep 30, 2019 | 27.51 Mn |